254 results on '"Massie, B M"'
Search Results
2. Supplement to: Irbesartan in patients with heart failure and preserved ejection fraction.
3. Effect of Nesiritide in Patients with Acute Decompensated Heart Failure
4. Mode of death in heart failure: findings from the ATLAS trial
5. Expression of skeletal muscle sarcoplasmic reticulum calcium-ATPase is reduced in rats with postinfarction heart failure
6. Relation of systemic and local muscle exercise capacity to skeletal muscle characteristics in men with congestive heart failure
7. Effects of rolofylline, a new adenosine A1 receptor antagonist, on symptoms, renal function and outcomes in patients with acute heart failure. Results from the PROTECT pilot study
8. Association of physician-determined worsening heart failure with signs and symptoms, hospitalization duration, and 60-days outcomes in patients hospitalised for acute heart failure
9. Diuretic response in acute heart failure: clinical characteristics and prognostic significance
10. Comparative effects of low and high doses of the angiotensin-converting enzyme inhibitor, Lisinopril, on morbidity and mortality in chronic heart failure
11. Treatment of heart failure in the elderly: never say it's too late
12. Review: available evidence does not support the use of blockers as first line treatment for hypertension
13. Evidence-based use of levosimendan in different clinical settings
14. Isosorbide dinitrate plus hydralazine was effective for advanced heart failure in black patients
15. The current role of amiodarone in patients with congestive heart failure
16. Beta-blockers reduce deaths from congestive heart failure
17. Myocardial metabolism during increased work states in the porcine left ventricle in vivo.
18. Can further benefit be achieved by adding flosequinan to patients with congestive heart failure who remain symptomatic on diuretic, digoxin, and an angiotensin converting enzyme inhibitor? Results of the flosequinan-ACE inhibitor trial (FACET).
19. Skeletal muscle size: relationship to muscle function in heart failure
20. Risk stratification for noncardiac surgery. How (and why)?
21. Endocardial versus epicardial differences of intracellular free calcium under normal and ischemic conditions in perfused rat hearts.
22. Effect of diuretic therapy on hypertensive left ventricular hypertrophy
23. Cardiac contractile dysfunction during mild coronary flow reductions is due to an altered calcium-pressure relationship in rat hearts.
24. Effect of supranormal coronary blood flow on energy metabolism and systolic function of porcine left ventricle
25. Neurophysiological assessment of skeletal muscle fatigue in patients with congestive heart failure.
26. Suppression of motion artifacts in fluorescence spectroscopy of perfused hearts
27. Exercise training in heart failure patients. Does reversing the peripheral abnormalities protect the heart?
28. Skeletal muscle function, morphology, and metabolism in patients with congestive heart failure
29. Response of high-energy phosphates and lactate release during prolonged regional ischemia in vivo.
30. Impaired skeletal muscle function in patients with congestive heart failure. Relationship to systemic exercise performance.
31. The dipyridamole-thallium test.
32. 31P MRS of myocardial inorganic phosphate using radiofrequency gradient echoes
33. Skeletal muscle response to exercise training in congestive heart failure.
34. Low doses vs. high doses of the angiotensin converting-enzyme inhibitor lisinopril in chronic heart failure: a cost-effectiveness analysis based on the Assessment of Treatment with Lisinopril and Survival (ATLAS) study. The ATLAS Study Group.
35. Acute coronary findings at autopsy in heart failure patients with sudden death: results from the assessment of treatment with lisinopril and survival (ATLAS) trial.
36. Veterans Affairs Quality Enhancement Research Initiative in chronic heart failure.
37. Management of heart failure. III. The role of revascularization in the treatment of patients with moderate or severe left ventricular systolic dysfunction.
38. Management of heart failure. II. Counseling, education, and lifestyle modifications.
39. Vasodilator treatment with isosorbide dinitrate and hydralazine in chronic heart failure.
40. Improved myocardial efficiency in the working perfused heart of the spontaneously hypertensive rat.
41. Heart failure 1997: a time to take stock.
42. The heart failure epidemic: magnitude of the problem and potential mitigating approaches.
43. Future approaches to pharmacologic therapy for congestive heart failure.
44. Hypertension, myocardial ischemia, and sudden death.
45. A personal perspective on the treatment of heart failure in 1994.
46. 31P MRS of myocardial inorganic phosphate using radiofrequency gradient echoes.
47. Acute coronary findings at autopsy in heart failure patients with sudden death: Results from the assessment of treatment with lisinopril and survival (ATLAS) trial
48. Efficacy and safety of high-dose lisinopril in chronic heart failure patients at high cardiovascular risk, including those with diabetes mellitus: Results from the ATLAS trial
49. Cytokine expression increases in nonmyocytes from rats with postinfarction heart failure
50. Acute and long-term effects of vasodilator therapy on resting and exercise hemodynamics and exercise tolerance.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.